Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation.
Azfar NeyazElisabeth S TabbAngela R ShihQing ZhaoStuti ShroffMartin S TaylorSteffen RickeltJennifer Y WoCarlos Fernandez-Del CastilloMotaz QadanTheodore S HongKeith D LillemoeDavid T TingCristina R FerroneVikram DeshpandePublished in: Histopathology (2020)
The high proportion of patients with PDAC showing complete and near-complete pathological responses supports the use of FOLFIRINOX and radiation in the neoadjuvant setting. Several traditional pathology parameters fail to predict OS in patients treated with chemoradiation, while a quantitative tumour-to-tumour bed ratio is a powerful predictor of OS. The data support a two-tiered approach to TRG based on tumour-to-tumour bed ratio, and quantitative analysis merits further consideration.